Bard Associates Inc. Makes New Investment in Paysign, Inc. (NASDAQ:PAYS)

Bard Associates Inc. bought a new position in shares of Paysign, Inc. (NASDAQ:PAYS) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 27,953 shares of the company’s stock, valued at approximately $103,000.

A number of other large investors have also modified their holdings of the business. Vanguard Group Inc. grew its holdings in shares of Paysign by 3.0% during the first quarter. Vanguard Group Inc. now owns 1,649,043 shares of the company’s stock worth $6,035,000 after buying an additional 48,489 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Paysign by 25.0% during the second quarter. Renaissance Technologies LLC now owns 1,504,380 shares of the company’s stock worth $6,484,000 after buying an additional 301,000 shares in the last quarter. Joule Financial LLC purchased a new stake in shares of Paysign during the third quarter worth $1,478,000. Royce & Associates LP purchased a new stake in shares of Paysign in the third quarter valued at about $814,000. Finally, GSA Capital Partners LLP grew its holdings in shares of Paysign by 31.2% in the third quarter. GSA Capital Partners LLP now owns 117,028 shares of the company’s stock valued at $429,000 after purchasing an additional 27,829 shares during the period. Hedge funds and other institutional investors own 25.89% of the company’s stock.

Paysign Price Performance

Shares of PAYS stock opened at $3.38 on Friday. The firm has a market cap of $181.00 million, a PE ratio of 22.80 and a beta of 0.95. The company has a 50-day moving average of $3.92 and a two-hundred day moving average of $4.33. Paysign, Inc. has a 1-year low of $2.22 and a 1-year high of $5.59.

Paysign (NASDAQ:PAYS) last issued its quarterly earnings results on Tuesday, November 5th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.02. The business had revenue of $15.26 million for the quarter, compared to analysts’ expectations of $14.96 million. Paysign had a net margin of 14.28% and a return on equity of 30.64%. During the same quarter in the prior year, the company earned $0.02 earnings per share. Sell-side analysts anticipate that Paysign, Inc. will post 0.21 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Barrington Research reissued an “outperform” rating and issued a $7.00 price objective on shares of Paysign in a report on Monday, November 4th.

Insider Activity at Paysign

In other Paysign news, CEO Mark Newcomer sold 50,000 shares of the stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $4.25, for a total value of $212,500.00. Following the transaction, the chief executive officer now directly owns 9,486,886 shares in the company, valued at $40,319,265.50. This represents a 0.52 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Matthew Louis Lanford sold 25,360 shares of the stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $3.96, for a total transaction of $100,425.60. Following the completion of the transaction, the insider now owns 109,731 shares in the company, valued at $434,534.76. This represents a 18.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 236,360 shares of company stock valued at $900,686 over the last 90 days. 23.40% of the stock is owned by corporate insiders.

About Paysign

Paysign, Inc provides prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing services for businesses, consumers, and government institutions. Its product offerings include solutions for corporate rewards, prepaid gift cards, general purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance, and demand deposit accounts accessible with a debit card.